{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:57:30Z","timestamp":1791273450880,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes and chronic kidney disease (CKD). These prespecified analyses assessed the effects of semaglutide on CV outcomes and death by CKD severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were randomized to subcutaneous semaglutide 1 mg or placebo weekly. The main outcome was a composite of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (CV death\/MI\/stroke) as well as death due to any cause by baseline CKD severity. CKD was categorized by estimated glomerular filtration rate &amp;lt; or \u226560 mL\/min\/1.73 m2, urine albumin-to-creatinine ratio &amp;lt; or \u2265300 mg\/g, or Kidney Disease Improving Global Outcomes (KDIGO) risk classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three thousand, five hundred and thirty-three participants were randomized with a median follow-up of 3.4 years. Low\/moderate KDIGO risk was present in 242 (6.8%), while 878 (24.9%) had high and 2412 (68.3%) had very high KDIGO risk. Semaglutide reduced CV death\/MI\/stroke by 18% [hazard ratio (HR) 0.82 (95% confidence interval 0.68\u20130.98); P = .03], with consistency across estimated glomerular filtration rate categories, urine albumin-to-creatinine ratio levels, and KDIGO risk classification (all P-interaction &amp;gt; .13). Death due to any cause was reduced by 20% [HR 0.80 (0.67\u20130.95); P = .01], with consistency across estimated glomerular filtration rate categories and KDIGO risk class (P-interaction .21 and .23, respectively). The P-interaction treatment effect for death due to any cause by urine albumin-to-creatinine ratio was .01 [&amp;lt;300 mg\/g HR 1.17 (0.83\u20131.65); \u2265300 mg\/g HR 0.70 (0.57\u20130.85)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide significantly reduced the risk of CV death\/MI\/stroke regardless of baseline CKD severity in participants with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae613","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T11:25:11Z","timestamp":1724498711000},"page":"1096-1108","source":"Crossref","is-referenced-by-count":60,"title":["Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial"],"prefix":"10.1093","volume":"46","author":[{"given":"Kenneth W","family":"Mahaffey","sequence":"first","affiliation":[{"name":"Stanford Center for Clinical Research, Department of Medicine, Stanford School of Medicine , 300 Pasteur Drive, Grant S-102, Stanford, Palo Alto, CA 94305 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Washington School of Medicine , Seattle, WA ,","place":["USA"]},{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Arici","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hacettepe University Faculty of Medicine , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M M","family":"Baeres","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Charytan","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York University Grossman School of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Chernin","sequence":"additional","affiliation":[{"name":"Kaplan Medical Center, Hebrew University of Jerusalem , Rehovot ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[{"name":"National Institute of Medical Sciences and Nutrition, Salvador Zubir\u00e1n , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gumprecht","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Idorn","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0397","authenticated-orcid":false,"given":"Giuseppe","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, La Sapienza University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Kirstine Bull","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen , Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Sokareva","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F E","family":"Mann","sequence":"additional","affiliation":[{"name":"KfH Kidney Centre , Munich ,","place":["Germany"]},{"name":"Department of Nephrology, Hypertension and Rheumatology, University Hospital, Friedrich-Alexander University , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-1389","authenticated-orcid":false,"given":"Richard","family":"Pratley","sequence":"additional","affiliation":[{"name":"AdventHealth Translational Research Institute , Orlando, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2025032407561884500_ehae613-B1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2025032407561884500_ehae613-B2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025032407561884500_ehae613-B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"2025032407561884500_ehae613-B4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2025032407561884500_ehae613-B6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B12","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B13","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2025032407561884500_ehae613-B14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"2025032407561884500_ehae613-B15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032407561884500_ehae613-B16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40256-024-00647-3","article-title":"Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials","volume":"24","author":"de Oliveira Almeida","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"2025032407561884500_ehae613-B17","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/17474930241253988","article-title":"Glucagon-like peptide-1 receptor agonists and stroke: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"19","author":"Adamou","year":"2024","journal-title":"Int J Stroke"},{"key":"2025032407561884500_ehae613-B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13098-023-01251-2","article-title":"Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Gu","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"2025032407561884500_ehae613-B19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.14740\/cr1523","article-title":"The impact of glucagon-like peptide-1 receptor agonist on the cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis and systematic review","volume":"14","author":"Rahman","year":"2023","journal-title":"Cardiol Res"},{"key":"2025032407561884500_ehae613-B20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025032407561884500_ehae613-B21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025032407561884500_ehae613-B23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025032407561884500_ehae613-B24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"2025032407561884500_ehae613-B25","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.ekir.2021.06.029","article-title":"Systematic review of cardiovascular outcome trials using new antidiabetic agents in CKD stratified by estimated GFR","volume":"6","author":"Arshad","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025032407561884500_ehae613-B26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2025032407561884500_ehae613-B27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025032407561884500_ehae613-B28","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B30","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032407561884500_ehae613-B31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/phar.2737","article-title":"Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis","volume":"42","author":"Kelly","year":"2022","journal-title":"Pharmacotherapy"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae613\/58963750\/ehae613.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/12\/1096\/59873466\/ehae613.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/12\/1096\/59873466\/ehae613.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T10:00:41Z","timestamp":1742983241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/12\/1096\/7745056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,8,30]]},"published-print":{"date-parts":[[2025,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae613","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,21]]},"published":{"date-parts":[[2024,8,30]]}}}